Tech Company Financing Transactions
Mirvie Funding Round
Mirvie, based in San Francisco, secured $60 million from Decheng Capital, BlackRock and Comerica Bank.
Transaction Overview
Company Name
Announced On
5/17/2022
Transaction Type
Debt
Venture Equity
Venture Equity
Amount
$60,000,000
Round
Series B
Investors
Decheng Capital (Lead Investor)
private investors (Allyson Felix)
Proceeds Purpose
The funding will support the company's continued clinical and commercial development of the proprietary Mirvie RNA platform, which predicts preeclampsia and preterm birth months before they happen by revealing the underlying biology of each pregnancy.
Company Information
Company Status
Private & Independent
Industry
Medical Devices & Instruments
Mailing Address
820 Dubuque Ave.
San Francisco, CA 94080
USA
San Francisco, CA 94080
USA
Phone
Website
Email Address
Overview
Mirvie is shaping the future of pregnancy health by providing women and their doctors with an early detection window to intervene before unexpected pregnancy complications become a crisis.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Stanley Lapidus
Chief Executive Officer
Maneesh Jain
Chief Medical Officer
Michal Elovitz
Chief Operating Officer
Manfred Lee
VP - Engineering
Hong Frank
VP - Finance
Karen Kirk
VP - Product Management
Carrie Haverty
VP - R & D
Eugeni Namsaraev
VP - R & D
Morten Rasmussen
Browse more venture capital transactions:
Prev: 5/17/2022: Buildots venture capital transaction
Next: 5/17/2022: Blinq Technologies venture capital transaction
Share this article
About Our VC Transactions Data
Our team works diligently to report on every notable VC transaction. VC investment data records on this site are sourced from a variety of public sources. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs